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Abstract The four-domain structure of human factor Vl la and 
the two-domain structure of tissue factor form a tight complex 
to initiate blood coagulation. By solution scattering, the mean 
X-ray and neutron radii of gyration Re (which determine macro- 
molecular elongation) were found to be 3.25 nm, 2.13 nm and 3.14 
nm (+ 0.13 rim) for factor VIIa, the extracellular egion of tissue 
factor and their complex in that order. The mean cross-sectional 
radii of gyration Rxs were 1.33 rim, 0.56 nm and 1.42 nm ( + 0.13 
nm) in that order. The mean lengths were 10.3 nm, 7.7 nm and 
10.2 nm in that order. The data show that, in solution, the free 
proteins have extended domain structures, and the complex is 
formed by a compact side-by-side alignment of the two proteins 
along their long axes. The high binding affinity of tissue factor 
for factor Vl la may thus be accounted for by the occurrence of 
many intermolecular contacts in the complex. 
Key words: Factor VIIa; Tissue factor; Protein structure; 
Coagulation; X-ray scattering; Neutron scattering 
1. Introduction 
Blood coagulation has long been recognised as an important 
process essential for survival. Inappropriate coagulation ob- 
structing blood vessels (or thrombosis) is responsible for much 
morbidity and mortality. Thrombotic disorders are often asso- 
ciated with cardiovascular, infectious and neoplastic disease. 
An understanding of the molecular basis of the procoagulant 
pathways will in the long term help to treat and even prevent 
many of these thrombotic disorders. Exposure of the mem- 
brane-bound receptor, tissue factor, to plasma initiates the co- 
agulation pathways. Upon cell-surface expression of tissue fac- 
tor, it forms a very stable catalytic enzyme-cofactor complex 
with the plasma serine protease coagulation factor VlIa 
(FVIIa) with a K a of binding estimated to be from 3 pM to 5 
nM [1,2]. 
Both tissue factor and FVIIa are multidomain proteins. The 
crystal structure for the soluble extracellular region of tissue 
*Corresponding author. Fax: (44) (171) 794-9645. 
E-mail: steve@rfhsm.ac.uk 
**Present address: Cardiovascular Department, Synth61abo 
Recherche, 31 Avenue Paul Vaillant Couturier, 92220 Bagneux, 
France. 
Abbreviations: FVIIa, factor VIIa; sTF, soluble extracellular tissue 
factor (residues 1-2193; SP, serine protease; EGF, epidermal growth 
factor. 
factor (sTF) [3,4] shows that this contains two C2-type immu- 
noglobulin fold domains. FVIIa contains four domains. The 
serine protease (SP) and epidermal growth factor (EGF-2) do- 
mains in the crystal structure of human factor Xa [5] are highly 
homologous inprimary structure to those found in FVIIa. The 
NMR structures of the EGF-1 domain of human factors IX 
and X [6,7] provide a close model for the EGF-I domain in 
FVIIa. Finally the known crystal structure of the N-terminal 
Gla domain of prothrombin [8] may be used as a model for that 
in FVIIa. While an atomic model for FVIIa can be proposed, 
there is no information on the relative spatial arrangement of 
its four domains. In addition, no data is available for the struc- 
ture of the FVIIa-sTF complex. 
Neutron and X-ray scattering studies provide the means, not 
only for determining the domain orientation of FVIIa, and 
verifying that for sTF, but also for determining a low resolution 
structure of the enzyme-cofactor c mplex [9,10]. A complete set 
of neutron and X-ray data is reported which characterise the 
radius of gyration of the overall structure R G and its cross- 
section Rxs, and the distance distribution function P(r). We 
show ttlat the FVIIa-sTF complex possesses a compact struc- 
ture. This offers an explanation for the high affinity of the two 
proteins for each other in the complex in terms of the ability 
of many residues, identified from biochemical studies, to form 
specific interrnolecular interactions in the complex. 
2. Materials and methods 
2.1. Preparations of factor VIIa, tissue factor and their complex 
Recombinant wild-type human FVII was expressed in CHO cells [11] 
and purified to homogeneity b monoclonal ntibody affinity chroma- 
tography [12] or with final purification carried out using a Resource Q
ion-exchange column (Pharmacia, StAlbans, UK). FVIIa was derived 
by autoactivation at 2~, mg/ml in TBS-Ca buffer (50 mM Tris/150 mM 
NaCI/5 mM CaCI2 pH 7.4) at room temperature for 18 h, covalently 
inactivated at the active site by treatment with dansyl-Glu-Gly-Arg- 
chloromethyl ketone (DEGR-CK, Calbiochem), followed by rechro- 
matography on Mono Q (Pharmacia) to isolate pure FVIIa. Shortly 
prior to data collection, FVIIa was subjected togel-filtration on Super- 
ose 12 (Pharmacia) inTBS-Ca to remove trace aggregates, then recon- 
centrated using Centricon-30 devices (Amicon, Stonehouse, UK). In 
one experiment, purified non-activated FVII was prepared in TBS 
without prior autoactivation, and was found to be fully activated after 
data collection. Control experiments indicated that autoactivation is 
rapid in concentrated solutions of FVII. 
Recombinant sTF (residues 1-219) was isolated from E. coil cell 
paste and purified as described previously [13], or alternatively by 
sequential ion-exchange chromatography onSP Sepharose High Per- 
formance and Resource Qcolumns (Pharmacia). The resulting protein 
was subjected to gel filtration as above before final reconcentration 
using Centricon-10 devices (Amicon) prior to data collection. 
The complex was formed from FVIIa and sTF, which were purified 
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as above, concentrated to volumes of 500 ¢tl each, then mixed in TBS- 
Ca at 37°C for 5 rain in a molar ratio of FVIIa:sTF of approximately 
1 : 2 as determined by the absorbance at280 nm. The sTF-FVIIa com- 
plex was separated from excess sTF by gel filtration on Superose 12. 
Fractions from an elution peak corresponding to the complex were 
pooled and concentrated, sTF was eluted in a later peak as demon- 
strated by SDS-PAGE analysis [14]. Concentrations c were calculated 
from calculated absorbance measurements at 280 nm using absorption 
coefficients (1%, 1 cm) of 12.8, 15.6 and 13.7 for FVIIa, sTF and their 
complex, respectively [15]. Sequences and carbohydrate contents were 
obtained from refs. [1(~20]. 
Scattering data were obtained using TBS-Ca buffer in t-I20 buffers 
for X-ray work, while the neutron work involved dialysis at 6°C into 
the corresponding buffer in 2H20 for at least 36 h with four buffer 
changes. SDS-PAGE under non-reducing conditions before and after 
scattering was used to verify the integrity of the samples. Samples were 
stored at 4-6°C until required. X-ray and neutron data collection was 
performed at 15°C using thermostatted sample holders. 
2.2. X-ray and neutron data collection 
X-ray curves were obtained in two beam sessions on cameras at 
Stations 2.1 and 8.2, both equipped with a quadrant detector, at the 
Synchrotron Radiation Source at Daresbury [21]. Sample-detector dis- 
tances of 3.14 m and 3.46 m were used, with beam currents of 136 mA 
to 203 mA and a storage ring energy of 2.0 GeV. This setup resulted 
in an available Q range of between 0.06 to 2.38 nm ~ (Q = 4x sin0/2; 
scattering angle = 20; wavelength -- 2). Samples were measured inTef- 
lon cells with 15-20/lm thick mica windows. Data were recorded using 
10 time frames to monitor possible radiation damage ffects. Other 
details of instrument calibration and data reduction are described else- 
where (e.g. in [22]). 
Neutron data were obtained uring three beam sessions on the LOQ 
scattering instrument at the ISIS facility at the Rutherford Appleton 
Laboratory, Didcot, UK [23]. The pulsed neutron beam was derived 
from bombardment of a tantalum or depleted uranium target by 170- 
185/IA proton beam currents. A 3He ORDELA wire detector was 
employed at a sample-to-detector distance of 4.3 m, and yielded an 
available Q range of 0.05 2.2 nm 1 Samples were measured in 2 mm- 
thick rectangular quartz Hellma cells. Other details are described else- 
where (e.g. in [22,24]). 
2.3. Analysis of reduced X-ray and neutron data 
In a given protein-buffer scattering contrast, the radius of gyration 
R6 is a measure of structural elongation if the internal inhomogeneity 
of scattering densities within the glycoprotein can be neglected. Analy- 
ses of the I(Q) curves at small Q in Guinier plots give the Ra and the 
forward scattering at zero scattering angle I(0) [25]: 
In I(Q) = In I(O)-RG2Q213. 
The relative values of l(O)lc (c = sample concentration) gives relative 
molecular weights Mr of the proteins as a control of the data [26]. If 
the structure is sufficiently elongated, the averaged radius of gyration 
of the cross-sectional structure Rxs and the averaged cross-sectional 
intensity at zero angle [I(Q). Q]e-~0 are obtained from [25,27]: 
In [I(Q).Q] = In [I(Q). Q]Q~0 - RxsZQ 2/2. 
The/~. and Rxs analyses lead to estimates of triaxial dimensions, where 
in particular the length of the longest axis L = [12(Rc2-Rxs2)] 1/2 or 
L : gI(O)I[I(Q). Q]o-~o [25,281. 
Indirect ransformation f the full scattering data in reciprocal space 
I(Q) into that in real space P(r) was carried out using the GNOM 
program of Svergun [29]. 
P(r) = ~ I(Q).Qr.sin(Qr)'dQ 
P(r) corresponds to the distribution of distances r between any two 
volume elements within one particle. This offers an alternative calcula- 
tion of RG and/(0), and gives the maximum dimension of the macro- 
molecule L. To calculate the P(r) curves, the X-ray I(Q) curves con- 
tained 350-390 data points extending out to 2.2 nm -1 and the neutron 
I(Q) curves contained 69 data points extending out to 2.1 nm -1. Dma ~ 
was varied in 1 nm steps between 5-20 nm to test the stability of the 
P(r) transformation. L was determined from the value of r when P(r) 
became zero at large r; however, errors in L can be significant for reason 
of the low intensity of P(r) in this region. 
3. Resu l t s  
3.1. Synchrotron X-ray data on factor VIIa, extracellular t&sue 
jactor and their complex 
The full X-ray scattering curves I(Q) of FVIIa, sTF and their 
complex were analysed in two distinct Q ranges at low Q in 
order to obtain the radius of gyration R G and the cross-sec- 
tional radius of gyration Rxs. Figs. 1 and 2 show that the final 
Rc and Rxs data were obtained from linear plots in satisfactory 
QR G and QRxs ranges. For  FVIIa, noticeable radiation dam- 
age effects were observed at low Q through apparent aggregate 
formation. These were analysed using data collected in 10 con- 
secutive 1 min time frames. The RG and I(0) parameters were 
stable for the first 2 min of data collection, then increased 
linearly with time for the remaining 8min. X-ray data for FVI Ia  
in Figs. 1-3 were analysed using only the first 1 min time-frame. 
Analyses of the dilution series between 0.6-2.5 mg FVI Ia/ml 
showed no concentration dependence of the RG or I(O)lc values 
(c: sample concentration), sTF was stable in the X-ray beam 
and the entire 10 rain data acquisition with 0.9 mg sTF/ml was 
used for Guinier analyses. The complex (3.9 mg/ml) exhibited 
slight radiation damage, and the first three time-frames only 
were used for all data analyses. 
The mean X-ray R G value of FVI Ia which defines its overall 
elongation is 3.24 _+ 0.08 nm (Table 1). The Rc, lRo ratio indi- 
cates the anisotropy or the degree of elongation of the struc- 
ture, where R o is the R G of the sphere with the same hydrated 
volume as the protein in question. The RclR o ratio is 
1.53 + 0.04 for FVIIa, which is slightly higher than the aver- 
aged value of 1.28 _+ 0.10 for single-domain globular proteins 
[9]. The overall solution structure of FVI Ia is thus extended. Its 
mean Rxs value was 1.53 + 0.13 nm. Calculation of the length 
L of FVI Ia by two methods from the Guinier analyses (section 
2) suggests a value of L between 9.9 nm to 11.4 nm. The mean 
X-ray R G of sTF was determined to be 1.99 _+ 0.05 nm, and 
resulted in an RG/R o ratio of 1.19 + 0.03. Its mean Rxs value 
is 0.52 nm, and its length L is 6.7 to 7.6 nm. The mean R G of 
the complex was 3.20 +0.02 nm, its RclRo ratio was 
1.33 + 0.01, its mean Rxs value was 1.56 + 0.02 nm, and its 
length L was between 9.7 nm to 11.2 nm. The structural ani- 
sotropy of the complex was therefore intermediate between 
those of FVI Ia and sTF. However sedimentation data have 
suggested that the frictional ratio fifo of the complex is 1.52, 
which is larger than that for FVI Ia of 1.39, and implies that the 
complex is more elongated than FVI Ia [30]. 
The distance distribution function P(r) allows the determina- 
tion of the maximum dimension L (section 2). The R G and I(0) 
parameters calculated from P(r) were all in good agreement 
with the Guinier analyses (Table 1). The X-ray P(r) curve for 
FVI Ia reached a maximum at r -- 3.0 nm to correspond to the 
most frequently occurring distance within FVIIa. The maxima 
for sTF and the complex were at 1.2 nm and 3.0 nm. L was 
determined to be 10 + 2 nm for FVIIa, 8.0 + 0.1 nm for sTF 
and 10.2 _+ 0.3 nm for the complex. These were in agreement 
with the Guinier length calculations (Table 1). It is concluded 
that the length of the longest axis of the complex is similar to 
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Table 1 
Summary of solution scattering data for factor VIIa, extracellular tissue factor and their complex 
Q ranges used in Guinier fits (nm -~) 
Guinier analysis Re (nm) Rxs (nm) L (nm):Re 
L (nm) :I(0) 
P(r) analysis Re (nm) L (rim) M (nm) 
Factor VIIa 
0.204).42 0.6-1.4 
X-ray (7) 1 3.24 + 0.08 1.53 + 0.13 9.9 + 0.2 
11.4 + 0.5 
3.37+_0.05 10 _+2 3.0+_0.3 
Neutron (3) 3.22 + 0.02 1.13 + 0.03 10.4 +_ 0.1 
10.0 _+ 1.0 
3.18 + 0.05 10 -+ 2 2.5 +_ 0.1 
Tissue factor 
0.184).60 0.7 1.4 
X-ray (4) 1.99 + 0.05 0.52 + 0.01 6.7 _+ 0.2 
7.6 -+ 0.3 
2.12 + 0.12 8.0_+ 0.1 1.2 +_ 0.1 
Neutron (1) 2.08 + 0.04 0.59 + 0.03 6.9 -+ 0.2 
8.2-+0.1 
2.32 + 0.13 9.0 1.6 
Complex 
0.15-0.49 0.(~1.0 
X-ray (2) 3.20 + 0.02 1.56 + 0.02 9.7 _+ 0.1 
11.2_+0.1 
3.23 _+ 0.03 10.2 _+ 0.3 3.0 
Neutron (1) 3.04 + 0.08 1.27 _+ 0.05 9.6 _+ 0.4 
10.8 + 0.6 
3.10 _+ 0.13 9.5 2.9 
t Values are given as the mean + standard eviation of a total of separate measurements a  bracketted. For single runs, the standard eviation 
corresponds to that of the Guinier or P(r) fits. The X-ray and neutron Q ranges used for Guinier fits is shown above each set of R e and Rxs values. 
The L values correspond to the longest dimension of the macromolecule calculated as defined in section 2. 
that of FVIIa. In other words, FVIIa and sTF form a side-by- 
side complex which leaves the overall length unchanged. 
3.2. Neutron data on factor Vlla, extraeellular tissue factor and 
their complex 
Neutron scattering data were obtained for FVIIa, sTF and 
their complex in 100% 2H20 buffers. This corresponds to a 
negative solute-solvent contrast, compared to the positive con- 
trast of the X-ray measurements [9,10]. The data served as a 
control of X-ray radiation damage (as no radiation effects 
occur with neutrons), and possible effects from large internal 
scattering density variations within FVIIa and the complex due 
to glycosylation. The Guinier analyses resulted in linear plots 
(Figs. 1 and 2). Values of c were 3.9 7,5 mg/ml for FVIIa, 0.9 
mg/ml for sTF, and 2.6 mg/ml for the complex. No aggregation 
commonly observed with the use of 2H20 buffers was ob- 
served. 
The corresponding sets of X-ray and neutron Guinier and 
P(r) data in Table 1 generally showed good agreements with 
each other. This again demonstrated that the complex is inter- 
mediate in its structural anisotropy between those of FVIIa and 
sTF. Two exceptions to this agreement were the Rxs values for 
FVIIa and the complex, which were significantly reduced by 
neutrons compared to the X-ray values. This is attributed to the 
high electron density of carbohydrate relative to protein, which 
will cause the observed X-ray Rxs value to increase, and the 
neutron Rxs to decrease. Surface carbohydrate can have a large 
effect on solution scattering curves. Use of the average of the 
X-ray and neutron values will approximately represent a struc- 
ture at infinite contrast by analogy with the Stuhrmann rela- 
tionship, in which this contrast effect is minimised [9,10,25]. 
As the neutron intensities had been standardized using a 
deuterated polymer standard [23], the Guinier l(O)/c values for 
FVIIa, sTF and their complex could be compared with I(O)/c 
values for other proteins of known molecular weights. The 
I(O)lc value for FVIIa and the complex were determined to be 
0.051 and 0.072, respectively. The ratio of I(O)lc values is 
0.71:1.00, which is close to the ratio of 0.67:1.00 
expected from the M r values of 51,400 and 76,200. No calcula- 
tion was made for sTF as c was too low for an accurate l(O)lc 
value. Both I(O)lc values were consistent with values of 0.093 
for recombinant human IgE-Fc (Mr of 75,300) [22] and 0.181 
for bovine IgG1 and IgG2 (Mr of 144,000) [24]. It is concluded 
that the complex was formed as expected. 
4. Discuss ion 
The solution scattering data show that FVIIa, sTF and their 
complex were monomeric, and that low resolution structural 
parameters can be derived from these. The X-ray and neutron 
data were self-consistent, and each data set served as a control 
of the other. Since the results can be averaged, the mean X- 
ray and neutron R~ values were computed from Table 1 to be 
3.25 nm, 2.13 nm and 3.14 nm ( + 0.13 nm) for FVIIa, sTF and 
their complex respectively. The mean Rxs values were 1.33 nm, 
0.56 nm and 1.42 nm ( _+ 0.13 nm), and the mean lengths L were 
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10.3 rim, 7.7 nm and 10.2 nm, respectively. Even though the 
molecular weights of FVIIa and sTF are comparable at51,400 
and 24,800, it is clearly seen that formation of the complex did 
not lead to significantly increased Re or L values. These dimen- 
sions were very similar for FVIIa and the complex, indicating 
that the complex has a compact structure. This implies that 
many residues in both FVIIa and sTF will be in sufficiently 
close proximity to form intermolecular interactions to stabilise 
the complex. Both domains of sTF are expected to make such 
contacts with FVIIa, in agreement with the biochemical data 
[2], and there will be much scope for the design of anticoagu- 
lants that will prevent complex formation. 
Fig. 4 indicates a schematic outline of the structures of the 
two free proteins and their mode of association i the complex 
as suggested from the scattering data. The interface between the 
EGF-2 and SP domains in the crystal structure of Factor Xa 
is defined by many contacts [5], and is presumed to be similar 
in FVIIa. The N- and C-terminal c~-carbon atoms of the FVIIa 
Gla, EGF-I and EGF-2 domains were arranged to lie on one 
linear axis. On this basis, the length of FVIIa in Fig. 4 is 10.2 
nm, which agrees with the L values of Table 1, and suggests hat 
the N-terminal domains of FVIIa are extended in solution. The 
length of sTF from the crystal structure is 8.3 nm, which also 
agrees with Table 1. The side-by-side model for the complex in 
Fig. 4 is consistent with biochemical data which show that a 
fragment of FVIIa containing both the Gla and EGF-1 do- 
mains inhibit complex formation [31]. Since the Gla domain of 
blood coagulation proteases i thought o bind to cell mem- 
branes, and full length tissue factor is associated with cell mem- 
branes via a C-terminal transmembrane region, it can be pre- 
sumed that the two domains of sTF are aligned with the C- 
domain next to the Gla domain in the complex (Fig. 4). Ulti- 
mately the combination of the scattering curves in Figs. 1-3 
with a recently-developed method of automated curve fitting of 
domain models to the scattering curves (which is constrained 
using known atomic structures for individual domains [22,24]) 
should permit he quantitative t sting of sterically-allowed do- 
main structures in FVIIa, sTF and their complex to produce 
improved low-resolution structures compared to those pre- 
sented in Fig. 4. 
Following completion of the present structural studies, a 
report has been made of a crystal structure of active site-inhib- 
ited FVIIa and a subtilisin-cleaved extracellular region of tissue 
factor [32]. This showed that a compact complex is formed with 
FVIIa and tissue factor positioned side-by-side, which is in 
good agreement with the scattering data. 
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